Scarica l'app Stockscreener
3.63
1.68%
0.06
Dopo l'orario di chiusura:
3.65
0.02
+0.55%
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 34% Share Price Rise - simplywall.st
AVEROA - The Pharma Letter
AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times
AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.
Akebia Therapeutics expands stock incentive plan - Investing.com Australia
Akebia Therapeutics expands stock incentive plan By Investing.com - Investing.com South Africa
Akebia Therapeutics Approves Stock Plan Amendment at Meeting - TipRanks
Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026 - Seeking Alpha
Day 7 of Gains Streak for Akebia Therapeutics Stock with 38% Return (vs. 109% YTD) [6/6/2025] - Trefis
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating - MSN
Akebia Therapeutics at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and Corporate UpdatesA... - ADVFN
Akebia reports mixed results for anemia drug in global study By Investing.com - Investing.com South Africa
Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying - Seeking Alpha
Akebia reports mixed results for anemia drug in global study - Investing.com Australia
Akebia Therapeutics (AKBA) Receives 'Buy' Rating from HC Wainwri - GuruFocus
Akebia (AKBA) Publishes Phase 3 Clinical Trial Analysis | AKBA S - GuruFocus
Akebia Therapeutics Announces Publication of Pre-specified Analyses on Vadadustat from Global Phase 3 Clinical Program in Journal of the American Society of Nephrology - Nasdaq
Vadadustat U.S. Patient Data from Global Phase 3 Clinical - GlobeNewswire
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology - Yahoo Finance
H.C. Wainwright assumes coverage on Akebia Therapeutics stock with buy rating - Investing.com
Akebia (AKBA) Receives Buy Rating with Promising Outlook for Vaf - GuruFocus
Akebia Ther stock soars to 52-week high, hits $3.31 By Investing.com - Investing.com South Africa
Akebia Ther stock soars to 52-week high, hits $3.31 - Investing.com Australia
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Expands Team with Strategic New Hires, Grants $415,000 in Stock Options - Stock Titan
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025 - GlobeNewswire
Kidney Disease Leader Akebia Therapeutics Sets Major Investor Presentation at Jefferies Healthcare Conference - Stock Titan
Akebia’s patent for Anemia therapy gets fresh blood from Court - BananaIP
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025 - GlobeNewswire
Akebia Unveils Critical Cardiovascular Safety Analysis for Vadadustat in Dialysis Patients at ERA Congress - Stock Titan
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Northern Trust Corp Has $3.20 Million Stock Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Akebia Therapeutics stock soars to 52-week high of $2.91 By Investing.com - Investing.com India
Akebia Therapeutics at H.C. Wainwright Conference: Vafseo’s Strategic Launch By Investing.com - Investing.com Canada
Akebia Therapeutics stock soars to 52-week high of $2.91 - Investing.com Australia
Certain Common Stock of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Certain Stock Options of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Certain Rights of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Certain Warrants of Akebia Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 19-MAY-2025. - marketscreener.com
Price T Rowe Associates Inc. MD Has $263,000 Holdings in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Voya Investment Management LLC - Defense World
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results - GuruFocus
2.01%
0.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):